Related Experiment Video
Updated: Dec 29, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC)
Caroline Conceição da Guarda1, Sètondji Cocou Modeste Alexandre Yahouédéhou1, Rayra Pereira Santiago1
1Laboratório de Investigação em Genética e Hematologia Translacional, Instituto Gonçalo Moniz, FIOCRUZ-BA, Salvador, Bahia, Brasil.
Insights
Sickle cell anemia (SCA) and SC hemoglobinopathy (HbSC) show distinct clinical and lab differences. SCA patients have more severe anemia and inflammation, while HbSC patients show higher lipid levels, impacting disease monitoring.
Area of Science:
- Hematology
- Genetics
- Clinical Medicine
Background:
- Sickle cell disease (SCD) encompasses various hemoglobinopathies with diverse clinical outcomes.
- Sickle cell anemia (SCA) is generally more severe than SC hemoglobinopathy (HbSC).
- Understanding genotype-specific differences is crucial for effective SCD management.
Purpose of the Study:
- To compare clinical manifestations and laboratory parameters between SCA and HbSC genotypes.
- To identify distinct biomarkers for monitoring disease progression in different SCD types.
- To investigate the association of clinical events with specific biomarkers.
Main Methods:
- Cross-sectional study design.
- Inclusion of 126 SCA and 55 HbSC individuals in steady-state.
- Comprehensive hematological, biochemical, and inflammatory assessments, including clinical event history and cluster analysis.
Main Results:
- SCA patients presented with more pronounced anemia, hemolysis, leukocytosis, and inflammation compared to HbSC patients.
- HbSC patients exhibited elevated lipid levels.
- Pain crises were the primary reason for hospitalization in both groups, linked to various biomarkers.
Conclusions:
- SCA and HbSC, despite genetic similarities, display unique clinical and laboratory profiles.
- Biomarker profiles differ between SCA and HbSC, aiding in genotype-specific monitoring.
- These findings support tailored clinical management strategies for different SCD genotypes.
Abstract:
Sickle cell disease (SCD) consists of a group of hemoglobinopathies in which individuals present highly variable clinical manifestations. Sickle cell anemia (SCA) is the most severe form, while SC hemoglobinopathy (HbSC) is thought to be milder. Thus, we investigated the clinical manifestations and laboratory parameters by comparing each SCD genotype. We designed a cross-sectional study including 126 SCA individuals and 55 HbSC individuals in steady-state. Hematological, biochemical and inflammatory characterization was performed as well as investigation of previous history of clinical events. SCA patients exhibited most prominent anemia, hemolysis, leukocytosis and inflammation, whereas HbSC patients had increased lipid determinations. The main cause of hospitalization was pain crises on both genotypes. Vaso-occlusive events and pain crises were associated with hematological, inflammatory and anemia biomarkers on both groups. Cluster analysis reveals hematological, inflammatory, hemolytic, endothelial dysfunction and anemia biomarkers in HbSC disease as well as SCA. The results found herein corroborate with previous studies suggesting that SCA and HbSC, although may be similar from the genetic point of view, exhibit different clinical manifestations and laboratory alterations which are useful to monitor the clinical course of each genotype.
Related Concept Videos
Multiple Allele Traits
Blood Types
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...
Genetic Lingo
Test for Homogeneity
Genetic Variation
Genes exist in different versions called alleles,...
Multipotency of Hematopoietic Stem Cells

